With this assumption, the drop-out rate in our model for Haryana declines from 10% to 8% between 2010 and 2024. Mortality and morbidity averted as a result of Hib vaccination would include 7 067 817 cases and 31 331 deaths (994 564 DALYs).
Delivering a primary-level non-communicable disease programme for Syrian refugees and the host population in Jordan: a descriptive costing study Hence the introduction of this vaccine will not only help in reducing the disease burden, but it will also prevent the regressive effects of high out-of-pocket payments for health care in India.The current price of pentavalent vaccine in India is US$1.75 (Various studies elsewhere have also found the introduction of Hib vaccine into national immunization schedules to be cost-effective. We carried out a sensitivity analysis using the uncertainty range for different parameters, which was reflective of state-wise differences in the parameter estimates in India.
Vaccinating children against Hib has been very effective in cutting rates of Hib infections. Policy Process And Non-State Actors’ Influence On The 2014 Mexican Soda Tax Risk of falling ill as a result of Hib disease peaks at mid-infancy or early childhood, and gradually wanes thereafter. Travel cost to the health facility and cost of treatment was obtained from the local surveillance report of pneumonia and meningitis in Khizrabad block, Haryana (Estimated cost of treatment from government and societal perspectives (US$)Estimated cost of treatment from government and societal perspectives (US$)We undertook a univariate sensitivity analysis to assess the impact of uncertainty in parameter values on cost-effectiveness estimates. School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, India With Hib cases accounting for only 5% of the total ALRI burden, introduction of Hib vaccine in the universal immunization programme will cost US$1336 per DALY averted, which is also within cost-effective bounds according to the WHO threshold (between 1 to 3 times per capita GDP).In order of decreasing importance, other determinants of cost-effectiveness included vaccination coverage, efficacy of vaccine and incidence of Hib meningitis (This study has demonstrated that the introduction of Hib vaccine in the universal immunization schedule is cost-effective in Haryana state of India. This gives a ratio of about 31.7 DALYs per death averted. Search for other works by this author on: In this model-based analysis for the United States population, we estimated the population health and economic outcomes that would result from use of an HIV vaccine with efficacy similar to that … Findings The incremental cost of Hib vaccine introduction from a government and a societal perspective was estimated to be US$81.4 and US$27.5 million, respectively, from 2010 to 2024. Worldwide, most cases of In India, since Hib vaccination is not done routinely, a cost-effectiveness study can be useful for policy makers in deciding whether to introduce the vaccine in the universal immunization schedule. Search for other works by this author on: Search for other works by this author on: In its position paper on Hib conjugate vaccine, WHO has recommended inclusion of Hib vaccination in all countries (A limitation of this study is that the cost of additional training for implementing the vaccine as part of routine immunization was considered minimal.
United Nations Children Fund, India Country Office. pentavalent (DPT-HBV-Hib) vs DPT and HBV vaccine. Risk of falling ill as a result of Hib disease peaks at mid-infancy or early childhood, and gradually wanes thereafter. Pentavalent vaccines provide protection against diphtheria, tetanus, pertussis (DTP), hepatitis B (HepB) and Haemophilus Influenzae type b (Hib). UNICEF procured $2.634 billion worth of goods in 2019. A multicentre surveillance study, where one centre was Khizrabad block in Yamunanagar district in Haryana (The incidence of Hib meningitis in under-5s was estimated to be 7.1 [95% confidence interval (CI) 3.1 to 14] per 100 000 child years of observation based on a prospective surveillance study in Vellore, Tamil Nadu during 1997 and 1999 (The age distribution of all invasive Hib disease cases was assumed to be 60% aged <12 months, 30% aged 12–23 months, 5% 24–35 months, 4% 36–47 months and 1% aged 48–59 months, based on the study by the Invasive Bacterial Infections Surveillance Group (Efficacy against Hib disease from one, two and three doses of Hib vaccine was assumed to be 47%, 75% and 95%, respectively (We estimated the cost-effectiveness of pentavalent Hib vaccine (DPT+HepB+Hib) introduction in Haryana. The National Family Health Survey (NFHS) and District Level Household Survey (DLHS) estimates of DPT vaccine coverage were used to estimate historical vaccination coverage and as a basis for extrapolating the future trend from 2010 to 2024 (Coverage of DPT2 and DPT3 was calculated by multiplying the DPT1 coverage by the DPT1 to DPT2 and DPT1 to DPT3 dropout rate, respectively, as estimated in NFHS-3.